Brief: Can-Fite Reports Second Quarter 2023 Financial Results
Aug 31 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS &
PROGRESS IN TWO PIVOTAL PHASE III CLINICAL STUDIES
* CAN FITE BIOPHARMA LTD - AS OF JUNE 30, 2023, CAN-FITE HAD
CASH
AND CASH EQUIVALENTS AND SHORT TERM DEPOSITS OF $9.60 MILLION
Source text for Eikon: ID:nBw51wpXqa
Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage